{"id":"NCT04993339","sponsor":"University of Miami","briefTitle":"Clinical Outcomes of ACL Reconstruction Augmented by an Injectable Osteoconductive/Osteoinductive Compound","officialTitle":"Clinical Outcomes of ACL Reconstruction Augmented by an Injectable Osteoconductive/Osteoinductive Compound","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-24","primaryCompletion":"2020-02-20","completion":"2020-02-20","firstPosted":"2021-08-06","resultsPosted":"2021-09-05","lastUpdate":"2021-09-05"},"enrollment":26,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["ACL Injury"],"interventions":[{"type":"DRUG","name":"OOC","otherNames":["StimuBlast"]}],"arms":[{"label":"Standard Surgery","type":"NO_INTERVENTION"},{"label":"Standard Surgery with OOC","type":"EXPERIMENTAL"}],"summary":"The goal of this study is to determine whether the use of injectable osteoinductive/osteoconductive compounds (OOC) during Anterior Cruciate Ligament (ACL) reconstructive surgery, combined with an accelerated rehabilitation protocol (ARP) provides clinical outcomes superior to those attained via traditional ACL reconstruction and delayed rehabilitation protocols.","primaryOutcome":{"measure":"Number of Participants With Bone Tunnel Expansion","timeFrame":"up to 12 months post-surgery","effectByArm":[{"arm":"Standard Surgery","deltaMin":0,"sd":null},{"arm":"Standard Surgery With OOC","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":14},"commonTop":[]}}